Status:
COMPLETED
Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients
Lead Sponsor:
Stanford University
Conditions:
Postpartum Hemorrhage
Pregnancy Related
Eligibility:
FEMALE
18-45 years
Phase:
EARLY_PHASE1
Brief Summary
Calcium is a life saving medicine in the care of parturients. It has many important uses including treatment of hypocalcemia, treatment of magnesium toxicity, prevention of hypocalcemia during blood t...
Eligibility Criteria
Inclusion
- Pregnant female subjects delivering at the study institution via scheduled cesarean delivery at term (\>=37 weeks gestation)
Exclusion
- severe range blood pressure (BP \>160/\>110) within the 48 hours prior to delivery
- patient age \<18 years or \>45 years
- renal dysfunction with serum Cr \> 1.0 mg/dL
- known history of congenital or acquired cardiac disease or history of arrhythmia
- patient taking digoxin
- patient currently taking a calcium channel blocker
- Weight \<55kg or \>100kg, or
- receiving magnesium infusion within 24 hours prior to or during cesarean delivery
- administration of intraoperative doses of calcium by the anesthesiology team for clinical indications
Key Trial Info
Start Date :
August 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT05973747
Start Date
August 19 2023
End Date
December 15 2023
Last Update
April 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lucile Packard Children's Hospital
Stanford, California, United States, 94305